文献速递胸部肿瘤

OAK研究更新疗效分析:阿替利珠单抗对比多西他赛二/三线治疗晚期NSCLC

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2018-05-17

OAK随机III期研究更新数据截止分析显示,在ITT850人群(n=850)中阿替利珠单抗对比多西他赛总生存HR=0.75(95%CI 0.64-0.89,p=0.0006),ITT1225人群(n=1225)HR=0.80(95%CI 0.70-0.92,p=0.0012),各PD-L1及组织学亚组均见生存获益,安全性优于多西他赛。

要点

  • 阿替利珠单抗二/三线治疗晚期NSCLC较长随访后持续显示对比多西他赛的OS获益
  • ITT850与ITT1225更新分析结果与主分析一致,各PD-L1及组织学亚组均获益
  • 3-4级治疗相关不良事件阿替利珠单抗14.9%、多西他赛42.4%,无阿替利珠单抗相关5级事件

核心结论

  • 更新数据截止时,阿替利珠单抗对比多西他赛在ITT850和ITT1225人群均显示总生存获益,与主疗效分析一致。
  • 阿替利珠单抗在更长治疗暴露和随访后仍维持有利的安全性特征,未观察到与阿替利珠单抗相关的5级不良事件。

研究设计与样本

  • 随机III期OAK研究的更新疗效分析,评估主要疗效人群(ITT850,n=850)与次要疗效人群(ITT1225,n=1225)。
  • 患者接受阿替利珠单抗1200 mg或多西他赛75 mg/m2静脉给药,每3周一次,直至失去临床获益或疾病进展。
  • 主要终点为ITT人群及PD-L1表达亚组的总生存;并开展敏感性分析评估多西他赛组后续免疫治疗对生存获益的影响。

主要发现

  • 更新后ITT850总生存HR=0.75(95%CI 0.64-0.89,p=0.0006),最低随访26个月。
  • ITT1225总生存HR=0.80(95%CI 0.70-0.92,p=0.0012),最低随访21个月。
  • 各PD-L1表达亚组及组织学亚组中均观察到阿替利珠单抗的生存改善。
  • 免疫治疗敏感性分析中,ITT850的HR=0.69、ITT1225的HR=0.74,相对生存获益略大于常规OS估计。
  • 3-4级治疗相关不良事件:阿替利珠单抗组14.9%,多西他赛组42.4%。

关键数值与推荐

  • ITT850更新OS:HR=0.75,95%CI 0.64-0.89,p=0.0006。
  • ITT1225更新OS:HR=0.80,95%CI 0.70-0.92,p=0.0012。
  • 免疫治疗敏感性分析OS:ITT850 HR=0.69,ITT1225 HR=0.74。
  • 3-4级治疗相关不良事件发生率:阿替利珠单抗14.9%,多西他赛42.4%。

临床怎么用

  • 支持阿替利珠单抗作为经治晚期NSCLC患者的二/三线治疗选择,各PD-L1及组织学亚组均可获益。
  • 较长治疗暴露下安全性仍优于多西他赛,3-4级治疗相关不良事件发生率更低,可指导临床用药选择与安全性管理。

局限性

  • 敏感性分析提示多西他赛组后续免疫治疗使用可能影响常规OS估计,解读生存获益时需考虑治疗交叉因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The efficacy and safety of atezolizumab versus the efficacy and safety of docetaxel as second- or third-line treatment in patients with advanced NSCLC in the primary (n = 850) and secondary (n = 1225) efficacy populations of the randomized phase III OAK study (respectively referred to as the intention-to-treat [ITT] 850 [ITT850] and ITT1225) at an updated data cutoff were assessed. METHODS: Patients received atezolizumab, 1200 mg, or docetaxel, 75 mg/m2, intravenously every 3 weeks until loss of clinical benefit or disease progression, respectively. The primary end point was overall survival (OS) in the ITT population and programmed death-ligand 1-expressing subgroup. A sensitivity analysis was conducted to evaluate the impact of subsequent immunotherapy use in the docetaxel arm on the observed survival benefit with atezolizumab. RESULTS: Atezolizumab demonstrated an OS benefit versus docetaxel in the updated ITT850 (hazard ratio [HR] = 0.75, 95% confidence interval: 0.64-0.89, p = 0.0006) and the ITT1225 (HR = 0.80, 95% confidence interval: 0.70-0.92, p = 0.0012) after minimum follow-up times of 26 and 21 months, respectively. Improved survival with atezolizumab was observed across programmed death-ligand 1 and histological subgroups. In the immunotherapy sensitivity analysis, the relative OS benefit with atezolizumab was slightly greater in the ITT850 (HR = 0.69) and ITT1225 (HR = 0.74) than the conventional OS estimate. Fewer patients receiving atezolizumab experienced grade 3 or 4 treatment-related adverse events (14.9%) than did patients receiving docetaxel (42.4%); no grade 5 adverse events related to atezolizumab were observed. CONCLUSIONS: The results of the updated ITT850 and initial ITT1225 analyses were consistent with those of the primary efficacy analysis demonstrating survival benefit with atezolizumab versus with docetaxel. Atezolizumab continued to demonstrate a favorable safety profile after longer treatment exposure and follow-up.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Fehrenbacher L, von Pawel J, Park K, et al. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 29777823. doi:10.1016/j.jtho.2018.04.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。